{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:52:46Z","timestamp":1794919966198,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm \/ Karolinska Institutet","id":[{"id":"https:\/\/ror.org\/056d84691","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2016-00398, 2021-01418"],"award-info":[{"award-number":["2016-00398, 2021-01418"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1136\/ard-2022-223762","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:20:39Z","timestamp":1676380839000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5735-9626","authenticated-orcid":false,"given":"Thomas","family":"Frisell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2046-3833","authenticated-orcid":false,"given":"Hannah","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-1476","authenticated-orcid":false,"given":"Matilda","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baecklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Di Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-5679","authenticated-orcid":false,"given":"Benedicte","family":"Delcoigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Feltelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7871-5303","authenticated-orcid":false,"given":"Helena","family":"Forsblad-d'Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-9348","authenticated-orcid":false,"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0433-0616","authenticated-orcid":false,"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd-Marie","family":"Ahlenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baecklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Feltelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Forsblad-d'Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alf","family":"Kastbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Klareskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223762_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological dmards: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pds.4381","article-title":"Strengthening Standards, transparency, and collaboration to support medicine evaluation: ten years of the European network of centres for pharmacoepidemiology and pharmacovigilance (encepp)","volume":"27","author":"Kurz","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2022-223762_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pds.5413","article-title":"Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018","volume":"31","author":"Sultana","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1136\/ard-2022-223762_bib6","doi-asserted-by":"crossref","first-page":"m3900","DOI":"10.1136\/bmj.m3900","article-title":"Grade approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223762_bib7","first-page":"S147","article-title":"The Swedish rheumatology quality register: optimisation of rheumatic disease assessments using register-enriched data","volume":"32","author":"Eriksson","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223762_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/03009742.2014.927918","article-title":"How good is the coverage and how accurate are exposure data in the Swedish biologics register (ARTIS)?","volume":"44","author":"Wadstr\u00f6m","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223762_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic health registry-based research: a review of health care systems and key registries","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1136\/ard-2022-223762_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib11","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib12","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1136\/ard-2022-223762_bib13","doi-asserted-by":"crossref","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-a nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223762_bib14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/rheumatology\/kez120","article-title":"Comment on: comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply","volume":"58","author":"Frisell","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib15","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bdmards in RA: results from a cohort study using nationwide Swedish register data","volume":"61","author":"Barbulescu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib16","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib17","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","article-title":"Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab","volume":"74","author":"Neovius","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/annrheumdis-2021-221996","article-title":"Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic dmards: results from four nordic countries","volume":"81","author":"Delcoigne","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/art.40084","article-title":"Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223762_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223762_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gr\u00f8n","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223762_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223762_bib24","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German rabbit register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1136\/ard-2022-223762_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223762_bib28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib29","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1136\/annrheumdis-2016-210127","article-title":"Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by scheinberg and azevedo","volume":"75","author":"Emery","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1136\/annrheumdis-2019-216702","article-title":"Hospital contacts due to hepatobiliary adverse events in > 5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries","volume":"79","author":"Glintborg","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib31","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1097\/pq9.0000000000000229","article-title":"Infliximab-induced depression and suicidal behavior in adolescent with Crohn's disease: case report and review of literature","volume":"4","author":"Shayowitz","year":"2019","journal-title":"Pediatr Qual Saf"},{"key":"10.1136\/ard-2022-223762_bib32","doi-asserted-by":"crossref","first-page":"172838","DOI":"10.1016\/j.pbb.2019.172838","article-title":"Efficacy of infliximab in treatment-resistant depression: a systematic review and meta-analysis","volume":"188","author":"Bavaresco","year":"2020","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1136\/ard-2022-223762_bib33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","article-title":"Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap","volume":"76","author":"Lacaille","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib34","first-page":"505","article-title":"Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study","volume":"59","author":"Provan","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib35","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/annrheumdis-2017-212395","article-title":"Patient characteristics influence the choice of biological drug in RA, and will make non-tnfi biologics appear more harmful than tnfi biologics","volume":"77","author":"Frisell","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib36","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","article-title":"Ten years with biologics: to whom do data on effectiveness and safety apply?","volume":"50","author":"Simard","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223762_bib37","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/03009734.2017.1285837","article-title":"Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective","volume":"122","author":"Feltelius","year":"2017","journal-title":"Ups J Med Sci"},{"key":"10.1136\/ard-2022-223762_bib38","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/14740338.2021.1909569","article-title":"Regulatory experience of handling risk management plans (rmps) for medicinal products in the EU","volume":"20","author":"Butler","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1136\/ard-2022-223762_bib39","series-title":"Patient registry initiative - strategy and mandate of the cross-committee task force","author":"Agency","year":"2017"},{"key":"10.1136\/ard-2022-223762_bib40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1136\/ard-2022-223762_bib41","first-page":"S79","article-title":"Primary and secondary patient data in contrast: the use of observational studies like rabbit","volume":"34","author":"Richter","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 4","key":"10.1136\/ard-2022-223762_bib42","doi-asserted-by":"crossref","first-page":"iv42","DOI":"10.1136\/ard.2005.042499","article-title":"The british society for rheumatology biologics register","volume":"64","author":"Watson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223762_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2022-eular.341","article-title":"POS0637 safety of B\/TSDMARDS for RA as used in clinical practice-results from the last decade of the artis program","volume":"81","author":"Frisell","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724084590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:35:44Z","timestamp":1739504144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724084590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003496724084590"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223762","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/ard-2022-223762.supp1","asserted-by":"subject"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}